PANDION THERAPEUTICS, INC. Research and Development Expense
PANDION THERAPEUTICS, INC. reported Research and Development Expense of $33.91 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-03-12
- PANDION THERAPEUTICS, INC. research and development expense for the quarter ending 2020-12-31 was $8.82M, a 133.81% increase year-over-year.
- PANDION THERAPEUTICS, INC. research and development expense for the quarter ending 2020-09-30 was $9.29M, a 111.72% increase year-over-year.
- PANDION THERAPEUTICS, INC. research and development expense for the quarter ending 2020-06-30 was $8.86M, a 79.57% increase year-over-year.
- PANDION THERAPEUTICS, INC. research and development expense for the quarter ending 2020-03-31 was $6.94M.
- PANDION THERAPEUTICS, INC. research and development expense for fiscal 2020 was $33.91M, a 86.54% increase from fiscal 2019.
- PANDION THERAPEUTICS, INC. research and development expense for fiscal 2019 was $18.18M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $18.10M derived: sum of 2 quarters · filed 2021-03-12 | $26.96M derived: sum of 3 quarters · filed 2021-03-12 | $33.91M 10-K · filed 2021-03-12 |
| 2020-09-30 | $9.29M 10-Q · filed 2020-11-16 | $18.15M derived: sum of 2 quarters · filed 2020-11-16 | $25.09M 10-Q · filed 2020-11-16 | $28.86M derived: sum of 4 quarters · filed 2021-03-12 |
| 2020-06-30 | $8.86M 10-Q · filed 2020-08-31 | $15.80M 10-Q · filed 2020-08-31 | $19.57M derived: sum of 3 quarters · filed 2021-03-12 | $23.96M derived: sum of 4 quarters · filed 2021-03-12 |
| 2020-03-31 | $6.94M derived: 10-K 12 month − 3 quarters · filed 2021-03-12 | $10.71M derived: sum of 2 quarters · filed 2021-03-12 | $15.10M derived: sum of 3 quarters · filed 2021-03-12 | $20.03M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $8.16M derived: sum of 2 quarters · filed 2021-03-12 | $13.09M derived: sum of 3 quarters · filed 2021-03-12 | $18.18M 10-K · filed 2021-03-12 |
| 2019-09-30 | $4.39M 10-Q · filed 2020-11-16 | $9.32M derived: sum of 2 quarters · filed 2020-11-16 | $14.40M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $4.93M 10-Q · filed 2020-08-31 | $10.02M 10-Q · filed 2020-08-31 |